Today on DrugResearcher.com   Merck and Neuromed feel the pain Jeol ups the ante with new 'entry level' NMR machine PerkinElmer reduces the cost of cellular imaging Charles River performs well in Q2 Nanoparticle tech to develop oral HIV vaccine

Related Industry News   Manufacturing partner for novel PEGylation tech PerkinElmer expands LC/MS validation service Outsourcing to Asia transitioning? GSK disappointed at FDA not approving Advair 500/50 strength

Breaking News on Drug Discovery
Daily  Thursday 09 August 2007		Forward to a colleague

	Sponsored Message Adenoviral shRNA and cDNA collections As the business service unit for Galapagos, a leading genomics-based drug discovery company, BioFocus DPI offers superior adenoviral tools and services to meet your target discovery and validation needs... Click Here Access Full Stories Merck and Neuromed feel the pain Merck & Co's latest bid to fill the gap left by the withdrawal of Vioxx (rofecoxib) has hit another stumbling block as it has dropped NMED-160 that it was developing in collaboration with Neuromed... Read Jeol ups the ante with new 'entry level' NMR machine Jeol has launched a new NMR (nuclear magnetic resonance) spectrometer that brings a high performance instrument to routine drug discovery and quality control applications, all in an 'entry level' package... Read PerkinElmer reduces the cost of cellular imaging PerkinElmer has launched an 'introductory configuration' of its Opera system to lower the upfront cost of adding high content screening (HCS) to drug discovery and systems biology programs... Read Charles River performs well in Q2 Charles River Laboratories posted healthy financial results for its second quarter, with both business units performing well... Read Nanoparticle tech to develop oral HIV vaccine Emerging specialty pharmaceutical company Nanotherapeutics will be using its nanoparticle drug delivery technology to develop an HIV oral peptide vaccine after entering into a two year agreement with the National... Read
	All News Headlines for: August | July | June
	Product Overview Pre-Clinical Contract Research - Free Download Pharmatest offers unique preclinical in vitro and in vivo drug efficacy testing services to pharmaceutical companies developing new drugs against osteoporosis, cancer or osteoarthritis. Our services can also be used for testing existing compounds for possible adverse effects on bone or secondary indication for bone-related diseases, as well as development of functional foods for bone health... Click Here
	Related Industry News Manufacturing partner for novel PEGylation tech A UK firm responsible for developing an innovative PEGylation technology has landed a deal with a Canadian specialty chemicals firm, allowing them to offer a complete package to companies looking to work with the... Read PerkinElmer expands LC/MS validation service PerkinElmer has expanded its multi-vendor service offering to help firms reduce the cost of regulatory compliance in pharmaceutical drug development and manufacturing quality control laboratories... Read Outsourcing to Asia transitioning? Big pharma's interest in outsourcing to Asia is shifting from drug manufacturing to clinical trials, new research reveals... Read GSK disappointed at FDA not approving Advair 500/50 strength GlaxoSmithKline (GSK) has suffered a blow in the advance if its top selling pharma drug Advair after US regulators issued a not approvable letter for an increased strength in the treatment of chronic obstructive... Read Outsourcing-Pharma.com special focus Court sanctions independent trustee for Inyx USA A US bankruptcy court judge ruled on Friday that Puerto Rican-based pharma services firm Inyx USA be put under the control of an independently-appointed trustee. Read Product Overview Innovative New Shaking Incubator from Stuart® A compact bench top incubator can be just enough for bacterial cell culturing. The latest shaking incubator from Stuart® is packed with novel features such as BioCote antimicrobial protection:... Click Here Previous Headlines Speculation on gene therapy trial death 'premature' Targeted Genetics said it was "premature as well as irresponsible" to draw any conclusions on what caused the death of a patient who participated in a clinical trial testing the safety of the firm's new gene therapy... Read Abraxis acquires rights to discovery platform Abraxis Bioscience has bought the worldwide rights to a discovery platform designed to generate new therapeutics and identify new drug targets that alter the p53 tumour suppressor signalling pathway... Read Biotech firm Archemix strengthens alliances Following Archemix' initial public offering (IPO) filing the company has announced two high profile strategic alliances aimed at leveraging its aptamer technology to a wider audience... Read Galapagos sees profit drop on spend hike; inks AZ contract Galapagos has reported a profit erosion for the first half of 2007 amidst accelerated R&D spend and business reshuffling. Meanwhile its services division has inked its third contract with AstraZeneca... Read Alzheimer's hits glaucoma between the eyes UK researchers have published results linking the beta amyloid protein associated with Alzheimer's disease to glaucoma, opening up a much needed new target for glaucoma therapies... Read Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analysis and instrumentation Assays and screening Cell culture & Equipment Chromatography Compounds and consumables Contract services (outsourcing) Drug discovery Genomics / Proteomics Informatics & IT Lab equipment & consumables Liquid handling and automation Liquid handling and sample preparation Production technologies Separation and purification

Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here

Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved La Tour du Triangle - 26, allee Jules Milhau - 34000 Montpellier - France http://www.decisionnewsmedia.com